Health1 min read

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

By · Via STAT Health · Published by Everything Blog

In short

Sellas Life Sciences reported that its experimental immunotherapy galinpepimut-S reduced the risk of death by 41% compared to standard therapy. The Phase 3 trial focused on individuals diagnosed with an advanced form of acute myeloid leukemia. By meeting its primary survival goal, the trial effectively refuted an earlier September column that anticipated the drug would fail.

Key points

  • Galinpepimut-S achieved its main therapeutic objective by significantly improving patient…: Galinpepimut-S achieved its main therapeutic objective by significantly improving patient survival rates against standard care.
  • The positive clinical findings directly countered skeptical predictions published in a Se…: The positive clinical findings directly countered skeptical predictions published in a September column regarding the drug's efficacy.
  • Sellas Life Sciences has secured critical Phase 3 validation for its advanced blood cance…: Sellas Life Sciences has secured critical Phase 3 validation for its advanced blood cancer treatment candidate.

Sources checked by our analysis pipeline: 1

It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.

On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.

In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health